# MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas

> **NCT06712875** · PHASE1,PHASE2 · RECRUITING · sponsor: **Ann & Robert H Lurie Children's Hospital of Chicago** · enrollment: 27 (estimated)

## Conditions studied

- Low Grade Glioma
- High Grade Glioma

## Interventions

- **DRUG:** Trametinib and Nivolumab
- **DRUG:** Dabrafenib, trametinib, nivolumab

## Key facts

- **NCT ID:** NCT06712875
- **Lead sponsor:** Ann & Robert H Lurie Children's Hospital of Chicago
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-04-01
- **Primary completion:** 2028-12
- **Final completion:** 2029-06
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2025-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06712875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06712875, "MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06712875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*